NextCell Pharma AB (NXTCL.ST)
SEK 2.42
(-13.57%)
SEK 2.42
(-13.57%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -37.82 Million | -43.82 Million | -33.31 Million | -25.57 Million | -18.95 Million | -22.13 Million |
| Net Income | -41.95 Million | -41 Million | -35.02 Million | -24.82 Million | -17.7 Million | -21.45 Million |
| Depreciation & Amortization | 974.66 Thousand | 447.87 Thousand | 457.34 Thousand | 437.02 Thousand | 397.1 Thousand | 348.25 Thousand |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 3.15 Million | -4.46 Million | 649.67 Thousand | -1.45 Million | -1.64 Million | -1.03 Million |
| Other non-cash items | - | 1.19 Million | 605.14 Thousand | 264.26 Thousand | -7213.00 | 2843.00 |
| Investing Cash Flow | -33.51 Thousand | -4.1 Million | -9.37 Million | -5.84 Million | -590.01 Thousand | -401.5 Thousand |
| Investments in PPE | -82.91 Thousand | -4.09 Million | -7.59 Million | -725.93 Thousand | -787.11 Thousand | -396.5 Thousand |
| Acquisitions | - | - | - | - | 280 Thousand | - |
| Investment purchases | - | -3149.00 | -1.75 Million | -5.11 Million | -82.9 Thousand | -5000.00 |
| Sales/Maturities of investments | 49.41 Thousand | - | - | - | -280 Thousand | - |
| Other Investing Activities | - | -3150.00 | -27 Thousand | -5.11 Million | 280 Thousand | -5000.00 |
| Financing Cash Flow | 34.62 Million | 835.66 Thousand | 608.16 Thousand | 148.62 Million | 21.38 Million | 39.54 Million |
| Debt repayment | - | -835.66 Thousand | -608.16 Thousand | -195.63 Thousand | -441.21 Thousand | -178.59 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 33.83 Million | - | - | 164.71 Million | 20.93 Million | 39.36 Million |
| Other Financing Activities | 795.66 Thousand | 835.66 Thousand | 608.16 Thousand | -16.09 Million | 441.21 Thousand | 178.59 Thousand |
| Accounts receivables | 3.11 Million | -7.58 Million | -1.55 Million | -3.23 Million | -1 Million | -1.14 Million |
| Accounts payables | -5.47 Million | 4.18 Million | 2.33 Million | 803.85 Thousand | -642.84 Thousand | 109.77 Thousand |
| Inventory | 245.42 Thousand | -23.69 Thousand | -766.96 Thousand | - | -301.38 Thousand | -109.77 Thousand |
| Other working capital | 5.26 Million | -1.03 Million | 642.94 Thousand | 977.9 Thousand | 301.38 Thousand | 109.77 Thousand |
| Cash at beginning of period | 50.02 Million | 97.11 Million | 139.16 Million | 21.95 Million | 20.12 Million | 3.11 Million |
| Cash at end of period | 46.79 Million | 50.02 Million | 97.11 Million | 139.16 Million | 21.95 Million | 20.12 Million |
| Capital Expenditure | -82.91 Thousand | -4.09 Million | -7.59 Million | -725.93 Thousand | -787.11 Thousand | -396.5 Thousand |
| Effect of forex changes on cash | - | - | 27 Thousand | - | -2.00 | - |
| Net cash flow / Change in cash | -3.23 Million | -47.09 Million | -42.05 Million | 117.2 Million | 1.83 Million | 17.01 Million |
| Free Cash Flow | -37.91 Million | -47.92 Million | -40.9 Million | -26.3 Million | -19.74 Million | -22.53 Million |
| Breakdown | 2024 Q4 | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -13.24 Million | -8.82 Million | -10.39 Million | -10.16 Million | -8.96 Million | -41 Million |
| Depreciation & Amortization | 646.71 Thousand | 102.91 Thousand | 113.06 Thousand | 111.97 Thousand | 111.96 Thousand | 447.87 Thousand |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 4.6 Million | -969.89 Thousand | -198.44 Thousand | -275.5 Thousand | -4.7 Million | -4.46 Million |
| Other non-cash items | 1.00 | -1.74 Million | -1.37 Million | 367.36 Thousand | 395.91 Thousand | 1.19 Million |
| Investing Cash Flow | 49.41 Thousand | - | -39.5 Thousand | -43.41 Thousand | -290.74 Thousand | -4.1 Million |
| Investments in PPE | 4.00 | - | -39.5 Thousand | -43.41 Thousand | -290.74 Thousand | -4.09 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | -3149.00 |
| Sales/Maturities of investments | 49.41 Thousand | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | -3150.00 |
| Financing Cash Flow | 33.94 Million | 93.07 Thousand | 182.53 Thousand | 405.77 Thousand | 246.21 Thousand | 835.66 Thousand |
| Debt repayment | - | -93.07 Thousand | -182.53 Thousand | -405.77 Thousand | -246.21 Thousand | -835.66 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 33.83 Million | - | - | - | - | - |
| Other Financing Activities | 114.28 Thousand | 93.07 Thousand | 182.53 Thousand | 405.77 Thousand | 246.21 Thousand | 835.66 Thousand |
| Accounts receivables | 4.88 Million | -280.31 Thousand | 566.99 Thousand | -2.05 Million | -6.19 Million | -7.58 Million |
| Accounts payables | -6.75 Million | 2.22 Million | -1.37 Million | 422.19 Thousand | 3.63 Million | 4.18 Million |
| Inventory | 245.42 Thousand | - | - | - | -23.69 Thousand | -23.69 Thousand |
| Other working capital | 6.21 Million | -2.91 Million | 604.8 Thousand | 1.35 Million | -2.11 Million | -1.03 Million |
| Cash at beginning of period | 20.79 Million | 30.39 Million | 40.42 Million | 50.02 Million | 63.22 Million | 97.11 Million |
| Cash at end of period | 46.79 Million | 20.79 Million | 30.39 Million | 40.42 Million | 50.02 Million | 50.02 Million |
| Capital Expenditure | 4.00 | - | -39.5 Thousand | -43.41 Thousand | -290.74 Thousand | -4.09 Million |
| Effect of forex changes on cash | - | - | - | 1.00 | 1.00 | - |
| Net cash flow / Change in cash | 25.99 Million | -9.59 Million | -10.03 Million | -9.59 Million | -13.2 Million | -47.09 Million |
| Free Cash Flow | -8 Million | -9.68 Million | -10.21 Million | -10 Million | -13.45 Million | -47.92 Million |
ZYXI
NNSB
4563
4078
CNXN
FRWDF